Clinical Advances of Retinal and Vitreous Diseases: Current Status and Prospect

Dear Colleagues,

Recent advancements in the management of retinal and vitreous diseases have led to significant improvements in clinical outcomes.

A major development was the introduction of anti-VEGF (vascular endothelial growth factor) therapies, transforming the treatment paradigm for age-related macular degeneration (AMD) and diabetic retinopathy. These therapies enhance visual acuity and slow disease progression by targeting underlying pathophysiological mechanisms.

Surgical interventions have also advanced, particularly with the adoption of minimally invasive techniques and novel 3D visualization systems. These innovations improve surgical precision and safety, allowing for the better visualization of retinal structures during procedures for retinal detachment and macular pathologies, resulting in improved outcomes and faster recovery times.

Additionally, advanced multimodal imaging technologies—including optical coherence tomography (OCT) and ultrawide-field imaging—have revolutionized diagnostics and monitoring. These technologies enable the integration of data from various techniques to provide dynamic representations of retinal structures, offering insights into the pathophysiology of diseases and facilitating the evaluation of important biomarkers for prognosis.

Current research, focusing on gene therapy, stem cell applications, and innovative drug delivery systems, holds substantial promise for enhancing treatment efficacy and improving the quality of life in patients with inherited retinal diseases.

The objective of this Special Issue is to highlight these advancements and foster further research and innovation in the clinical management of retinal and vitreous diseases, ultimately enhancing patient care and outcomes.

Dr. Lorenzo De Angelis
Dr. Francesco Barca
Prof. Dr. Stanislao Rizzo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.